Opinion|Videos|November 13, 2026

Managing Patient Expectations and the Oncology Access Gap

Setting realistic expectations around trials and biomarker testing — and the widening access gap, including drugs approved in Asia but unavailable in the US.

Desai: Let’s talk about managing patient expectations. We have many large clinical trials, some biomarker driven, and the key question is identifying the right patient for the right study. With so many options available, how do you manage expectations around personalized or tailored treatment?

Kydd: When I’m talking with patients, whatever the disease, somatic or germline genetic testing can sometimes bring additional agents to the table. That’s certainly true in bladder cancer, where we think about erdafitinib for FGFR3-altered disease, and in prostate cancer, where PARP inhibitors are an option for patients with homologous recombination repair (HRR) alterations such as BRCA1/2. We try to gather as much information as possible to know what’s in our toolkit, and we bring clinical trial conversations in early.

Kydd: At our institution we’re trying to be proactive about letting patients know what’s available, with a robust clinical trial portfolio so there is always something to offer. We’re also selective about which studies we open, so that even if a patient is randomized to the control arm, we feel the control arm is an appropriate standard of care for them. Sometimes we need to reset the expectation — a patient may feel bad that they weren’t assigned to the experimental arm, and we have to highlight that “experimental” means we’re still learning about it. We try to be enthusiastic about the trial and the agent while being honest that the agent may not come through. That balance of hope and realism is always part of the decision.

Desai: It is really important to manage expectations — to be hopeful about what a trial could show while staying realistic about not knowing the actual outcomes.

Kydd: Agreed. Even when it’s an investigational agent, we give the background on why we are hopeful. If this is a phase 3 study, we go back to the earlier phase trial to explain how we got here — trust, but verify. There is a body of evidence leading up to this point, and more evidence still to collect. Those are the expectations we set based on the evidence in hand, and on the uncertainties in hand.

Desai: Dr. Sun, let’s talk about the biggest gaps in our field — data-free zones, access, equity, infrastructure. Treatments are only good if they reach the patients who need them.

Sun: You bring up such a good point. As a country, we’re coming to a reckoning. For many years the United States was the privileged setting for drug access, and in many ways it still is — patients can usually, with some barriers, get the drugs they should be able to access. But I’ll give you an example that is niche but illustrates a pattern: in nasopharynx cancer, which I treat with some regularity in California, this is a rare disease in the United States. Only about 2% of global cases occur in North America. Most of the drug development happens in Asia — China has been a leader in nasopharynx cancer drug development, in part because they have the patient volume to run trials more quickly.

Sun: Several drugs are now approved in parts of Asia for nasopharynx cancer that are not yet approved in the United States for any indication. I know this data and I’m transparent with my patients — these are drugs that have been studied in large phase 3 randomized trials with clear benefit, but it may be a year or two before we have access here, and the fastest path to access in our patient population is usually the drug being approved in the US for another disease. That is extremely unsatisfying for a patient who knows an effective drug exists in another country but cannot access it, no matter what they do.

Desai: The same is true in GU. Access is really big. Not all centers have PSMA scans, for example, and many prostate cancer trials are PSMA based. Dr. Kydd, how do you think about access in the GU space, especially for patients who don’t have next-generation sequencing available in community settings?

Kydd: At Fox Chase Cancer Center and Temple University Health in the Philadelphia area — and extending into Pennsylvania, New Jersey, and Delaware — we see a mix: urban settings and more rural populations traveling in from a distance. Access to PSMA scans, radioligand therapy, and other modalities varies, and that spills over into the clinical trial setting as well. We try to be very intentional in making these things as accessible as possible.

Kydd: That includes how we talk with industry partners and how we design investigator-initiated trials, and how we coordinate across sites in our university hospital system so that trials are available at all sites with the staffing to deliver them. It is a years-long effort. Under our new cancer center director, Dr. Robert Winn, we’re also thinking about how communities help identify the questions we need to keep answering — both for drugs and for the delivery of care — because improving care delivery benefits everyone who comes through the door, here and nationally.

Desai: Those are really important points: partnerships with industry to bring agents and trials to our institutions, and partnerships with the community referral base so that colleagues keep referring patients to centers where these studies and drugs are available.

Kydd: Exactly. And when we design the studies themselves, if there are eligibility barriers that don’t reflect the populations we serve, we need to eliminate them. Those are the patients we are actually treating. Being creative and proactive about trial design is just as important as designing the next drug — if the trial excludes the patients who most need it, that’s not how we move the field forward.

Desai: Thank you all for the terrific discussion today. We’ve covered trends shaping the next few years of oncology, how to read evidence from a fast-moving pipeline, and what most excites or concerns us as clinicians navigating that change. Thank you to our panel and to our audience for joining this Peer Exchange.

Kydd: Thank you very much.


Related to this article